GlassScriptPhysician profile
Allison L Kovar
NPI 1942468111
$7,007.76
in general payments reported to CMS, 2019-2025
50 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $313 · 2021: $893 · 2022: $826 · 2023: $1,179 · 2024: $1,311 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361 · Travel and Lodging: $10.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,360.83 |
| Travel and Lodging | $10.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.03 | 2021-2025 | |
| Novo Nordisk INC | $837.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $650.19 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $446.40 | 2020-2025 | |
| Astellas Pharma US INC | $327.44 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $296.90 | 2020-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $285.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $283.14 | 2022-2025 | Rexulti |
| W. L. Gore & Associates, INC. | $231.42 | 2025 | Gore Synecor Biomaterial, Product In Development |
| Glaxosmithkline, LLC. | $230.08 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $202.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $168.50 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.99 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $148.02 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $143.00 | 2023-2025 | Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Kovar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.